For all of the quality care it delivers, the U.S. health care system is one of the most dysfunctional sectors of the U.S. economy. The government spends nearly 50 cents of every dollar spent on health care, most consumers are almost entirely insulated from the cost of their decisions, and employers decide what kind of health insurance their employees get.
But while the U.S. health care system begs for reform, the Patient Protection and Affordable Care Act only exacerbates all of the current problems, promising to devolve into a price-controlled system rationed and micromanaged by bureaucrats.
IPI believes there are much better options: reform the tax treatment of health insurance; remove the state and federal mandates and regulations that make coverage more expensive; pass medical liability reform; and promote policies that create value-conscious shoppers in the health care marketplace.
Important legislation has been proposed that would encourage medical and pharmaceutical manufacturing to relocate to the U.S. by providing potent tax incentives instead of threats of government force.
Americans are the world’s top users of generics, but not of biosimilars. State and local governments should encourage a wider uptake for their own employees as an important start—and a much-needed cost savings.
If a shot becomes available, there's a good chance more people will choose to vaccinate without a government mandate.
If the government determines that vaccinations are essential to stemming the spread of the disease, would it– could it–mandate vaccination compliance? Apparently, it can—and it might.
Was New York trying to send a social justice message that led to thousands of seniors in nursing homes dying of Covid-19?
Coalition Letter Regarding the Imposition of New Buy America Requirements for Medical Goods and Pharmaceutical Products
In this letter to the administration, economists from numerous organizations encourage the U.S. and its trading partners to pursue policies that make medical supplies more plentiful and affordable.
The BEAT CHINA Act is a “two-fer”—a major move toward a more pro-growth tax code and a carrot rather than a stick approach toward bringing critical manufacturing home.
Coalition letter in opposition to lawmakers actions that would deny patents, exclusivity, and property rights to biomedical innovators working on vaccines, diagnostics, therapies, and cures for COVID-19.
All models are wrong, and some are even harmful.
We know COVID-19 can be deadly, but determining how deadly isn't easy—even though trillions of taxpayers dollars depend on getting it right.